DR TIRUMANI RAGHU RAM PRASAD ,DR MOHAMED BILAL AZAM,DR R KANNAN,DR NISHAT J ,DR.B. SARAVANAKUMAR
DOI: https://doi.org/Background: Cirrhosis is a chronic liver condition marked by irreversible scarring of the liver and progressive liver dysfunction. Growth hormone (GH) has been posited as a therapeutic agent that might ameliorate some symptoms and biochemical markers of cirrhosis due to its anabolic and regenerative properties.Objective: This systematic review aims to synthesize available data from 15 studies to evaluate the effectiveness and safety of growth hormone therapy in patients with cirrhosis. Methods: A comprehensive literature search was conducted across multiple databases, including PubMed, Cochrane Library, and Scopus. Studies included in the review were those that assessed the clinical outcomes of GH therapy in cirrhotic patients, with data on liver function, clinical outcomes, adverse events, and quality of life metrics. Effectiveness and safety data were extracted and analyzed. Results: The review encompassed data from 15 studies, illustrating significant improvements in liver function tests and other clinical outcomes such as nutritional status and overall well-being. Most studies reported positive effects on liver biochemistry and patient vitality. However, adverse events associated with GH therapy, such as mild joint pain, hypertension, and elevated liver enzymes, were noted, though these were generally manageable and did not outweigh the benefits for most patients. Conclusion: Growth hormone therapy appears to offer beneficial effects in improving liver function and patient quality of life in cirrhotic populations, albeit with some manageable risks. The findings advocate for the integration of GH therapy into broader cirrhosis management protocols, with careful monitoring for adverse effects. Future research should focus on long-term outcomes and the development of tailored therapeutic regimens based on patient-specific disease etiologies and severities.
